Cooperative Agreement U44DA060264
Award Date
5/1/24
Completion Date
4/30/28
Dollars Obligated
$1.6M
Federal Agency
National Institute on Drug Abuse
Awardee
Instanosis Inc. (CA5GQKREPCE4)
Federal Grant Program
93.279
Assistance Type
Cooperative Agreement
Place of Performance
Philadelphia, PA 19146, USA
Similar Awards
This $586,936 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of a low-cost, disposable urine test strip for rapidly quantifying substance use disorder (SUD) medication drugs and their metabolites. The project aims to create a field-deployable, point-of-use diagnostic solution that enables fast, quantitative detection of drugs like buprenorphine, methadone, and naltrexone in patients'...
This $479,731 Project Grant was awarded on May 15, 2024 by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The funding supports the development of "NarcobondA2/MO", a "nanosponge" containing decoy receptors for the opioid fentanyl and the veterinary sedative xylazine. This novel biomimetic nanoparticle approach aims to sequester these dangerous drug cocktails in the peripheral blood, preventing their entry into the...
The National Institute on Drug Abuse (NIDA) awarded a $386,452 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The grant, with a performance period from April 1, 2025 to March 31, 2026, aims to support the development of rapid fingerstick diagnostics for the detection of opioid and stimulant use disorders. This aligns with NIDA's broader research focus on advancing scientific...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on studying the pharmacological properties of the drug xylazine and its metabolites. The $231,000 award runs from May 1, 2025 to April 30, 2027 and will be conducted by the University of Rochester. The key objectives are to determine if xylazine and its metabolites act as agonists, antagonists, or positive allosteric modulators at the mu,...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to better understand the behavioral pharmacology of opioid and xylazine (a veterinary sedative) combinations. The $392,940 award to the University of Texas Health Science Center at San Antonio will conduct experiments using established animal models to investigate why use of opioid/xylazine mixtures has increased, including whether...
This Project Grant award of $277,389 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to confirm the ability of the respiratory stimulant drug Etimizol to reverse the respiratory depression caused by the combination of the opioid fentanyl and the veterinary sedative xylazine. The award, with a performance period from January 15, 2025 to June 30, 2025, will fund preclinical studies by Synventa LLC, a small disadvantaged...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $238,500.00 over a 2-year period starting January 1, 2025 to examine the effects of the veterinary sedative xylazine on inhibitory brain circuits in the prefrontal cortex, and how these effects interact with opioid signaling. Specifically, the research aims to 1) test whether xylazine and opioids have synergistic effects on reducing inhibitory...
The National Institute on Drug Abuse (NIDA), through its Drug Use and Addiction Research Programs (CFDA 93.279), awarded a $399,589 Project Grant to Resilient Lifescience, Inc. The purpose of this grant, awarded on Sep 15, 2024, is to develop a wearable medical device to detect opioid overdose. The project is expected to be completed by Aug 31, 2025. The Drug Use and Addiction Research Programs support a wide range of research activities related to substance use disorders, addiction, and related...
This is a Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The goal of the $2,925,374 grant, awarded on August 1, 2024 and running through July 31, 2026, is to develop a reversal agent for overdoses involving the combination of fentanyl and xylazine. The awardee, Clear Scientific, LLC, a small for-profit company in Cambridge, Massachusetts, will study two candidate compounds - CS-1103 and CS-1105 - that can...
This Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $408,486 to the Research Triangle Institute (RTI International) to conduct a community-based, longitudinal, mixed-methods study investigating the growing crisis of xylazine exposure among people who use drugs in the Southeastern U.S. The study aims to: 1) employ community-based drug checking to determine the prevalence of xylazine in the illicit drug...